Heterotopic heart valve implantation offers a promising transcatheter strategy to address severe tricuspid regurgitation and right heart failure in high-risk patients.
Absolute Event Rate: 0% vs 0%
Tricuspid regurgitation (TR) is a prevalent, undertreated condition associated with debilitating symptoms and poor outcomes. While optimal medical therapy (OMT) remains foundational in heart failure (HF) management, it has limited impact on the pathophysiologic consequences of severe TR; particularly systemic venous congestion, right heart failure, and end-organ dysfunction. Surgical correction carries considerable operative risk, prompting the development of transcatheter strategies for these high-risk patients.
Labin et al. (Sun,) reported a other. Heterotopic heart valve implantation offers a promising transcatheter strategy to address severe tricuspid regurgitation and right heart failure in high-risk patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: